메뉴 건너뛰기




Volumn 6, Issue 1, 2017, Pages

Novel TGF-β inhibitors ready for prime time in onco-immunology

Author keywords

Belagenpumatucel L; Clinical trials; Fresolimumab; Galunisertib; Gemogenovatucel T; Trabedersen; XOMA089

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BELAGENPUMATUCEL L; DURVALUMAB; FRESOLIMUMAB; GALUNISERTIB; GEMCITABINE; GEMOGENOVATUCEL T; IMIDAZOLE; IMIDAZOPYRIDINE DERIVATIVE; ISOTHIAZOLE DERIVATIVE; LY550410; LY580276; MODAFINIL; NIVOLUMAB; PYRAZOLE; SB 505124; SORAFENIB; TRABEDERSEN; TRANSFORMING GROWTH FACTOR BETA INHIBITOR; TRIAZOLE; UNCLASSIFIED DRUG; XOMA089;

EID: 85031091457     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1257453     Document Type: Article
Times cited : (161)

References (12)
  • 2
    • 84866742560 scopus 로고    scopus 로고
    • TGFβ signalling in context
    • PMID:22992590
    • Massagué J. TGFβ signalling in context. Nat Rev Mol Cell Biol 2012; 13:616-30; PMID:22992590; http://dx.doi.org/10.1038/nrm3434
    • (2012) Nat Rev Mol Cell Biol , vol.13 , pp. 616-630
    • Massagué, J.1
  • 3
    • 84899071195 scopus 로고    scopus 로고
    • Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/ pharmacodynamic model
    • PMID:24843434
    • Gueorguieva I, Cleverly AL, Stauber A, Sada Pillay N, Rodon JA, Miles CP, Yingling JM, Lahn MM. Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/ pharmacodynamic model. Br J Clin Pharmacol 2014; 77:796-807; PMID:24843434; http://dx.doi.org/10.1111/bcp.12256
    • (2014) Br J Clin Pharmacol , vol.77 , pp. 796-807
    • Gueorguieva, I.1    Cleverly, A.L.2    Stauber, A.3    Sada Pillay, N.4    Rodon, J.A.5    Miles, C.P.6    Yingling, J.M.7    Lahn, M.M.8
  • 4
    • 85009903727 scopus 로고    scopus 로고
    • A phase II, double-blind study of galunisertibCgemcitabine (GG) vs gemcitabineCplacebo (GP) in patients (pts) with unresectable pancreatic cancer (PC)
    • abstr 4019
    • Melisi D, Garcia-Carbonero R, Macarulla T, Pezet D, Deplanque G, Fuchs M, Trojan J, Oettle H, Kozloff M, Cleverly A et al. A phase II, double-blind study of galunisertibCgemcitabine (GG) vs gemcitabineCplacebo (GP) in patients (pts) with unresectable pancreatic cancer (PC). J Clin Oncol 2016; 34, (suppl; abstr 4019).
    • (2016) J Clin Oncol , vol.34 suppl
    • Melisi, D.1    Garcia-Carbonero, R.2    Macarulla, T.3    Pezet, D.4    Deplanque, G.5    Fuchs, M.6    Trojan, J.7    Oettle, H.8    Kozloff, M.9    Cleverly, A.10
  • 5
    • 84904426489 scopus 로고    scopus 로고
    • A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC)
    • abstr LBA173)
    • Faivre S, Santoro A, Kelley RK, Merle P, Gane E, Douillard J-Y, Waldschmidt D, Mulcahy MF, Costentin C, Minguez B et al. A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2014; 32, (suppl 3; abstr LBA173).
    • (2014) J Clin Oncol , vol.32 suppl 3
    • Faivre, S.1    Santoro, A.2    Kelley, R.K.3    Merle, P.4    Gane, E.5    Douillard, J.-Y.6    Waldschmidt, D.7    Mulcahy, M.F.8    Costentin, C.9    Minguez, B.10
  • 9
  • 10
    • 85034600692 scopus 로고    scopus 로고
    • OT-101: An anti-TGF-beta-2 antisense-primed tumors to subsequent chemotherapies
    • abstr e15727
    • Hwang L, Ng K, Wang W, Trieu VN. OT-101: An anti-TGF-beta-2 antisense-primed tumors to subsequent chemotherapies. J Clin Oncol 2016; 34, (suppl; abstr e15727).
    • (2016) J Clin Oncol , vol.34
    • Hwang, L.1    Ng, K.2    Wang, W.3    Trieu, V.N.4
  • 11
    • 84939789948 scopus 로고    scopus 로고
    • Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
    • PMID:25529192
    • Rodón J, Carducci M, Sepulveda-Sánchez JM, Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I, Cleverly A et al. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest New Drugs 2015; 33:357-70; PMID:25529192; http://dx.doi.org/10.1007/s10637-014-0192-4
    • (2015) Invest New Drugs , vol.33 , pp. 357-370
    • Rodón, J.1    Carducci, M.2    Sepulveda-Sánchez, J.M.3    Azaro, A.4    Calvo, E.5    Seoane, J.6    Braña, I.7    Sicart, E.8    Gueorguieva, I.9    Cleverly, A.10
  • 12
    • 85009885916 scopus 로고    scopus 로고
    • A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-β) receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP)
    • abstr 4070
    • Faivre S, Santoro A, Gane E, Kelley RK, Ollivier-Hourmand I, Gueorguieva I, Cleverly A, Desaiah D, Lahn MM, Raymond E et al. A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-β) receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP). J Clin Oncol 2016; 34, (suppl; abstr 4070)
    • (2016) J Clin Oncol , vol.34
    • Faivre, S.1    Santoro, A.2    Gane, E.3    Kelley, R.K.4    Ollivier-Hourmand, I.5    Gueorguieva, I.6    Cleverly, A.7    Desaiah, D.8    Lahn, M.M.9    Raymond, E.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.